In a study, use of anticoagulants was associated with 85% fewer atherosclerotic events.
In a trial, oral calcitriol of 0.5 mcg daily did not reduce hepcidin levels in patients with stage 3 to 4 CKD.
Dialysis patients receiving more or less than 200 mg per month of IV iron had similar risks of death, infection, cardiovascular disease, and hospitalization, meta-analysis shows.
The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.
In a 52-week trial, more than half of nondialysis-dependent chronic kidney disease patients with anemia treated with oral iron had no rise in their hemoglobin levels.
Patients with hemoglobin values of 9.7 g/dL or below had more than double the risk for hemorrhagic stroke compared with patients with hemoglobin values of 11.2 g/dL or above.
The safety profile of CERA is similar for children as for adults.
To support ESA therapy, IV iron at doses below 300 mg/month may be most effective for the average hemodialysis patient, according to an observational study.
Urinary ceruloplamin has potential to be a chronic kidney disease biomarker for patients with sickle cell anemia.
Researchers tested once weekly and biweekly administration of darbepoetin alfa in children aged 1 to 18 years not previously treated with an erythropoiesis-stimulating agent.
Researchers find no significant difference in the median erythropoietin resistance index between patients with versus without residual renal function.
To shed light on the often-challenging management of this common condition, a case of a hypothetical patient was presented to a doctor who specializes in advanced heart failure and transplant cardiology.
High doses of iron are associated with a significantly higher risk of cardiovascular disease, regardless of the dose of erythropoiesis-stimulating agent.
Study results show that the phosphate binder was superior to placebo in raising hemoglobin levels in non-dialysis-dependent CKD patients with iron-deficiency anemia.
Intravenous iron and erythropoietin produced a similar hemoglobin response among hemodialysis patients with moderate anemia.
The group targeting higher hemoglobin values experienced less decline in graft function.
HD patients with untreated or ineffectively treated anemia prior to dialysis initiation were more likely to die than those who had consistently well-treated anemia.
In a study, end-stage renal disease was 31% more likely to develop in CKD patients with versus without anemia.
CKD patients in the 3rd and 4th quartiles of c-terminal serum fibroblast growth factor 23 had a 74% and 73% higher risk for anemia compared with those in the 1st quartile.
Proteinuria and renin-angiotensin-aldosterone system inhibitors are independently associated with a significant 6-fold increased odds for anemia in patients with diabetic nephropathy.
No data to suggest that nonvoluntary nature of donations compromises safety of blood products.
Findings based upon time costs of preparation and administration per patient.
In a randomized study of patients with heart failure, including some with concurrent chronic kidney disease, patients who received vitamin D supplements or placebo had similar changes in hemoglobin levels over 36 months.
Anemia much more common among patients who did not have close follow-up with weight-loss surgeon
In a survey, hemodialysis patients were willing to accept medication risks to avoid red blood cell transfusion.
Study of Japanese individuals showed that anemia increased mortality risk even in the absence of chronic kidney disease.
The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.
Up to a 49% higher risk of death observed in patients who had a 400 ng/mL increase in serum ferritin from baseline values compared with patients who had relatively stable ferritin levels.
Japanese researchers conclude that a serum ferritin level below 90 ng/mL and TSAT of 20% or higher was optimal for achieving a hemoglobin level of 10 g/dL or higher.
Researchers used pulse wave analysis to measure subendocardial viability ratio, a measure of myocardial perfusion, and its association with hemoglobin.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)